Allergy Therapeutics Posts Bigger FY25 Loss; Revenue Down

MT Newswires · 3d ago
02:49 AM EST, 12/11/2025 (MT Newswires) -- Allergy Therapeutics (AGY.L) on Thursday reported a wider loss for fiscal 2025, while revenue declined year over year. Loss attributable to equity shareholders for the 12 months ended June 30 was 40.1 million pounds sterling, compared with a loss of 38.6 million pounds earlier. Loss per share was 0.0084 pound, compared with the prior loss per share of 0.0103 pound. The British biotechnology company's revenue was 55 million pounds, compared with 55.2 million pounds a year ago.